Schizophrenia therapy options increasing

P and T

Volumn 39, Issue 9, 2014, Pages 646-647

  Gohil, Kunj ^a   Carramusa, Brielle ^a  

^a MediMedia Managed Markets   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ARIPIPRAZOLE LAUROXIL; ASENAPINE; BITOPERTIN; BREXPIPRAZOLE; CARIPRAZINE; CLOZAPINE; ENCENICLINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; LURASIDONE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; ZICRONAPINE; ZIPRASIDONE;

COGNITIVE DEFECT; DELUSION; DRUG APPROVAL; DRUG COST; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; SCHIZOPHRENIA;

EID: 84911487383     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Crismon L, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York: McGraw-Hill; 2014:1019–1046.
2. Global Data. Schizophrenia—Global Drug Forecast and Market Analysis to 2022. February 2014.
3. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007;12(10):904–922.
4. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry 2014;75(suppl 1):21–26.
5. Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 2013;7:1171–1180.